A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03901469

Recruitment Status : Terminated (Parts 1 and 2 and Expansion Cohort C were completed. Expansion Cohorts A and B were discontinued based on results from an interim futility analysis and not due to safety concerns.)

First Posted : April 3, 2019

Last Update Posted : May 3, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Pfizer

Newsoara Biopharma Co., Ltd.

Information provided by (Responsible Party):

Zenith Epigenetics

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	March 7, 2024
Actual Study Completion Date :	March 7, 2024

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kharenko OA, Patel RG, Calosing C, van der Horst EH. Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer. Cancer Gene Ther. 2022 Jun;29(6):859-869. doi: 10.1038/s41417-021-00375-9. Epub 2021 Aug 12.

To Top